Northland Biotech

Northland Biotech is a clinical-stage biopharmaceutical company based in Beijing, China, specializing in the development of gene therapies and recombinant protein drugs. The company's lead candidate, NL003, is a non-viral plasmid gene therapy encoding hepatocyte growth factor (HGF) currently in Phase 3 trials for critical limb ischemia. Other key programs include NL005, a recombinant human thymosin beta 4 for cardiovascular and ophthalmic indications, and NL002, a recombinant human erythropoietin. Northland Biotech operates its own R&D and manufacturing facilities, focusing on addressing unmet medical needs in vascular and metabolic diseases. The company is listed on the Beijing Stock Exchange and maintains a robust pipeline targeting chronic conditions with high clinical demand.